Demonstrates ocular surface toxicity in multiple myeloma patients using belantamab mafodotin, indicating the need for monitoring.
= .039). No significant nasal-temporal asymmetry was observed. Patients who discontinued belantamab mafodotin therapy due to keratopathy exhibited diffuse epithelial thinning relative to normal eyes, with disproportionate thinning in inferior mid-peripheral sectors. Sectoral AS-OCT mapping of the corneal epithelium may serve as an objective biomarker for quantifying belantamab mafodotin-associated ocular surface toxicity.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: